Provision for changes in expected cash flows from financial royalty assets
-197,485
23,105
12,135
-203,938
Provision for credit gaines on unfunded commitments
-3,700
-4,269
766
92,535
Research and development funding expense
39,790
50,500
50,500
300,500
General and administrative expenses (includes 122,292 and 703 of share-based compensation expense for the three months ended march 31, 2026 and 2025, respectively see note 4)
159,490
164,273
118,734
179,769
Financial royalty asset impairment
69,443
-
-
-
Total operating expense, net
67,538
233,609
182,135
368,866
Operating income
563,038
388,381
427,156
209,799
Equity in earnings of equity method investees
21,758
4,005
15,948
2,693
Interest expense
93,722
94,171
79,564
68,668
Losses on derivative financial instruments
-
-1,000
4,000
-2,000
Gaines on equity securities
-20,166
35,716
18,863
-30,553
Losses on available for sale debt securities
-6,680
24,080
52,480
-27,420
Interest income
6,229
7,071
6,903
8,327
Other non-operating expenses, net
-2,201
-8,169
-1,575
-1,543
Total other expense, net
-94,782
-32,468
17,055
-119,164
Consolidated net income before tax
468,256
355,913
444,211
90,635
Income tax expense
0
0
0
0
Consolidated net income
468,256
355,913
444,211
90,635
Net income attributable to non-controlling interests
173,566
141,708
155,994
60,459
Net income attributable to royalty pharma plc
294,690
214,205
288,217
30,176
Basic EPS
0.67
0.5
0.67
0.07
Diluted EPS
0.67
0.384
0.67
0.07
Basic Average Shares
436,790,000
428,323,000
431,887,000
423,514,000
Diluted Average Shares
556,837,000
557,809,000
559,611,000
562,298,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.